Nearly three-quarters of people carrying genetic mutations for familial hypercholesterolemia remain undiagnosed until they experience a heart attack, often before age 40. This represents a critical missed opportunity in preventive medicine, as early detection could transform cardiovascular outcomes for both young patients and their at-risk family members. Experts are raising concerns about recent cost-effectiveness modeling of universal youth lipid screening programs, arguing that flawed assumptions may lead health systems to abandon potentially life-saving early detection strategies. The genetic condition affects roughly 1 in 250 people and dramatically elevates LDL cholesterol from birth, creating arterial plaque decades earlier than typical cardiovascular disease. When identified in childhood, aggressive cholesterol management can prevent irreversible arterial damage and extend healthy lifespan significantly. The modeling controversy centers on whether current economic analyses adequately capture the full benefits of early intervention. Critics argue that existing studies may underestimate the cascade effect of finding one affected child, which typically leads to testing and treatment of multiple family members across generations. This multiplier effect could dramatically improve the cost-benefit equation beyond what current models suggest. The debate highlights a broader challenge in preventive medicine: how to accurately model the long-term value of interventions that prevent disease decades in the future. For familial hypercholesterolemia, where genetic testing and lipid-lowering therapy are well-established, the question isn't whether early treatment works, but whether health systems will prioritize population screening. Given that untreated FH patients face coronary disease risks 10-20 times higher than the general population, even conservative estimates suggest substantial potential for reducing premature cardiovascular mortality through systematic childhood screening programs.